Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended September 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
United States		$	—			$	—			$	—			$	—
International			7,516				—				—				7,516
Grant and other revenue			—				—				—				—
Total revenue			7,516				—				—				7,516
Cost of revenue, excluding depreciation and amortization			1,432				—				—				1,432
Reserve for expiring inventory			133,006				—				—				133,006
Research and development expenses			1,073,950				112,469				—				1,186,419
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				745				3,612,002				3,612,747
Depreciation and amortization ⁽²⁾			8,532				—				16,171				24,703
Income (loss) from operations ⁽³⁾			(1,209,404	)			(113,214	)			(3,628,173	)			(4,950,791	)
Other expense, net ⁽⁴⁾			—				—				(757,034	)			(757,034	)
Net loss			(1,209,404	)			(113,214	)			(4,385,207	)			(5,707,825	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	5,929,692			$	5,979,692
International			271,939				—				6,801				278,740
Capital expenditures			14,429				—				—				14,429

Three Months Ended September 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	9,116			$	—			$	—			$	9,116
Grant and other revenue			87,266				—				—				87,266
Total revenue			96,382				—				—				96,382
Research and development expenses			906,677				142,109				—				1,048,786
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				744				1,450,565				1,451,309
Depreciation and amortization ⁽²⁾			6,040				—				12,026				18,066
Loss from operations ⁽³⁾			(816,335	)			(142,853	)			(1,462,591	)			(2,421,779	)
Other expense, net ⁽⁴⁾			—				—				(14	)			(14	)
Income tax expense			(5,763	)			(824	)			(9,457	)			(16,043	)
Net loss			(822,098	)			(143,677	)			(1,472,062	)			(2,437,836	)
Total assets, net of depreciation and amortization:
United States		$	185,205			$	—			$	8,557,398			$	8,742,603
International			216,353				—				590				216,943
Capital expenditures			—				—				18,042				18,042

Nine Months Ended September 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
United States		$	—			$	—			$	—			$	—
International			14,035				—				—				14,035
Grant and other revenue			51,007				—				—				51,007
Total revenue			65,042				—				—				65,042
Cost of revenue, excluding depreciation and amortization			1,905				—				—				1,905
Reserve for expiring inventory			133,006				—				—				133,006
Research and development expenses			3,700,528				379,133				—				4,079,661
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,746				6,630,047				6,633,793
Depreciation and amortization ⁽²⁾			20,613				—				48,739				69,352
Loss from operations ⁽³⁾			(3,791,010	)			(382,879	)			(6,678,786	)			(10,852,675	)
Other expense, net ⁽⁴⁾			—				—				(841,853	)			(841,853	)
Net loss			(3,791,010	)			(382,879	)			(7,520,639	)			(11,694,528	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	5,929,692			$	5,979,692
International			271,939				—				6,801				278,740
Capital expenditures			54,650				—				8,436				63,086

Nine Months Ended September 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	44,665			$	—			$	—			$	44,665
Grant and other revenue			436,500				—				—				436,500
Total revenue			481,165				—				—				481,165
Research and development expenses			3,359,190				410,406				—				3,769,596
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,623				5,073,435				5,077,058
Depreciation and amortization ⁽²⁾			18,121				—				37,551				55,672
Loss from operations ⁽³⁾			(2,896,146	)			(414,029	)			(5,110,986	)			(8,421,161	)
Other income, net ⁽⁴⁾			—				—				358,436				358,436
Income tax expense			(5,763	)			(824	)			(9,457	)			(16,043	)
Net loss			(2,901,909	)			(414,853	)			(4,762,007	)			(8,078,768	)
Total assets, net of depreciation and amortization:
United States		$	185,205			$	—			$	8,557,398			$	8,742,603
International			216,353				—				590				216,943
Capital expenditures			—				—				20,749				20,749